Tumor immune evasion mediated by IDO

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Tumors actively create a state of immunologic tolerance toward themselves. One mechanism that may contribute to this condition of pathologic tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). Host dendritic cells expressing immunosuppressive IDO are found in tumor-draining lymph nodes, and IDO can also be expressed by tumor cells themselves. Either or both of these sites of IDO expression might serve to inhibit the immune response to tumors. Pharmacologic strategies to block the IDO pathway may be useful in helping to break the pre-established state of tolerance that exists in tumor-bearing hosts. Consistent with this possibility, in murine models the IDO inhibitor 1-methyl-tryptophan (1MT) has demonstrated significant synergy with several clinically relevant chemotherapeutic agents, initiating immune-mediated tumor regression following conventional chemotherapy. IDO inhibitor drugs may also reduce unwanted collateral immunosuppression by toll-like receptor (TLR) ligands such as CpG oligodeoxynucleotides, which can be potent inducers of IDO activity. Combination with IDO inhibitors may reduce suppression and the enhance efficacy of IDO-inducing agents such as CpG. IDO inhibitor drugs are thus potential immunomodulatory agents for cancer immunotherapy, and may display synergistic activity in combination both with chemotherapy and with other forms of immunotherapy.

Original languageEnglish (US)
Pages (from-to)175-185
Number of pages11
JournalUpdate on Cancer Therapeutics
Volume1
Issue number2
DOIs
StatePublished - Jun 1 2006

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Tumor Escape
Neoplasms
Immunotherapy
Drug Therapy
Oligodeoxyribonucleotides
Toll-Like Receptors
Immunosuppressive Agents
Pharmaceutical Preparations
Immunosuppression
Dendritic Cells

Keywords

  • Cancer
  • Chemotherapy
  • CpG oligodeoxynucleotides
  • Indoleamine 2,3-dioxygenase
  • Regulatory T cells
  • TLR9 ligands
  • Tolerance
  • Tryptophan
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tumor immune evasion mediated by IDO. / Munn, David H.

In: Update on Cancer Therapeutics, Vol. 1, No. 2, 01.06.2006, p. 175-185.

Research output: Contribution to journalReview article

@article{7e4d5f67e71047e5b5bcae5522516b8d,
title = "Tumor immune evasion mediated by IDO",
abstract = "Tumors actively create a state of immunologic tolerance toward themselves. One mechanism that may contribute to this condition of pathologic tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). Host dendritic cells expressing immunosuppressive IDO are found in tumor-draining lymph nodes, and IDO can also be expressed by tumor cells themselves. Either or both of these sites of IDO expression might serve to inhibit the immune response to tumors. Pharmacologic strategies to block the IDO pathway may be useful in helping to break the pre-established state of tolerance that exists in tumor-bearing hosts. Consistent with this possibility, in murine models the IDO inhibitor 1-methyl-tryptophan (1MT) has demonstrated significant synergy with several clinically relevant chemotherapeutic agents, initiating immune-mediated tumor regression following conventional chemotherapy. IDO inhibitor drugs may also reduce unwanted collateral immunosuppression by toll-like receptor (TLR) ligands such as CpG oligodeoxynucleotides, which can be potent inducers of IDO activity. Combination with IDO inhibitors may reduce suppression and the enhance efficacy of IDO-inducing agents such as CpG. IDO inhibitor drugs are thus potential immunomodulatory agents for cancer immunotherapy, and may display synergistic activity in combination both with chemotherapy and with other forms of immunotherapy.",
keywords = "Cancer, Chemotherapy, CpG oligodeoxynucleotides, Indoleamine 2,3-dioxygenase, Regulatory T cells, TLR9 ligands, Tolerance, Tryptophan, Tumor immunotherapy",
author = "Munn, {David H}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.uct.2006.05.009",
language = "English (US)",
volume = "1",
pages = "175--185",
journal = "Update on Cancer Therapeutics",
issn = "1872-115X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Tumor immune evasion mediated by IDO

AU - Munn, David H

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Tumors actively create a state of immunologic tolerance toward themselves. One mechanism that may contribute to this condition of pathologic tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). Host dendritic cells expressing immunosuppressive IDO are found in tumor-draining lymph nodes, and IDO can also be expressed by tumor cells themselves. Either or both of these sites of IDO expression might serve to inhibit the immune response to tumors. Pharmacologic strategies to block the IDO pathway may be useful in helping to break the pre-established state of tolerance that exists in tumor-bearing hosts. Consistent with this possibility, in murine models the IDO inhibitor 1-methyl-tryptophan (1MT) has demonstrated significant synergy with several clinically relevant chemotherapeutic agents, initiating immune-mediated tumor regression following conventional chemotherapy. IDO inhibitor drugs may also reduce unwanted collateral immunosuppression by toll-like receptor (TLR) ligands such as CpG oligodeoxynucleotides, which can be potent inducers of IDO activity. Combination with IDO inhibitors may reduce suppression and the enhance efficacy of IDO-inducing agents such as CpG. IDO inhibitor drugs are thus potential immunomodulatory agents for cancer immunotherapy, and may display synergistic activity in combination both with chemotherapy and with other forms of immunotherapy.

AB - Tumors actively create a state of immunologic tolerance toward themselves. One mechanism that may contribute to this condition of pathologic tolerance is the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). Host dendritic cells expressing immunosuppressive IDO are found in tumor-draining lymph nodes, and IDO can also be expressed by tumor cells themselves. Either or both of these sites of IDO expression might serve to inhibit the immune response to tumors. Pharmacologic strategies to block the IDO pathway may be useful in helping to break the pre-established state of tolerance that exists in tumor-bearing hosts. Consistent with this possibility, in murine models the IDO inhibitor 1-methyl-tryptophan (1MT) has demonstrated significant synergy with several clinically relevant chemotherapeutic agents, initiating immune-mediated tumor regression following conventional chemotherapy. IDO inhibitor drugs may also reduce unwanted collateral immunosuppression by toll-like receptor (TLR) ligands such as CpG oligodeoxynucleotides, which can be potent inducers of IDO activity. Combination with IDO inhibitors may reduce suppression and the enhance efficacy of IDO-inducing agents such as CpG. IDO inhibitor drugs are thus potential immunomodulatory agents for cancer immunotherapy, and may display synergistic activity in combination both with chemotherapy and with other forms of immunotherapy.

KW - Cancer

KW - Chemotherapy

KW - CpG oligodeoxynucleotides

KW - Indoleamine 2,3-dioxygenase

KW - Regulatory T cells

KW - TLR9 ligands

KW - Tolerance

KW - Tryptophan

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33746301440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746301440&partnerID=8YFLogxK

U2 - 10.1016/j.uct.2006.05.009

DO - 10.1016/j.uct.2006.05.009

M3 - Review article

VL - 1

SP - 175

EP - 185

JO - Update on Cancer Therapeutics

JF - Update on Cancer Therapeutics

SN - 1872-115X

IS - 2

ER -